All In MedTech

FDA Clearance Tracker · P190030

ActaStim-S Spine Fusion Stimulator

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Dec 9, 2020 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Dec 9, 2020

Approved (reclassified)

Time to decision

387 days

Received Nov 18, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class II

The decision

FDA number
P190030
Device name
ActaStim-S Spine Fusion Stimulator
Applicant location
Manassas, VA
Received
Nov 18, 2019
Decided
Dec 9, 2020
Decision
Approved (reclassified)
Supplements
4 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class II
Regulation
21 CFR 890.5870

Every decision under product code LOF

FDA's approval statement

As written in FDA's record.

Approval for the ActaStim-S Spine Fusion Stimulator is a noninvasive bone growth stimulator indicated as an adjunct electrical treatment to primary lumbar spinal fusion surgery for one or two levels. The device is Rx only, and intended for single patient use in adult patients only.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LOF. The earliest in FDA's data is P790002, decided Nov 6, 1979.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Theragen, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.